Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis
Authors:
Open Access
- 24 December 2024
- journal article
- research article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 26 (1) , 2441511
Abstract
Neoadjuvant chemotherapy (NAC) has proven valuable in treating locally advanced colon cancer (LACC) and is included as a treatment option for patients with clinical T4b colon cancer by the National Comprehensive Cancer Network. However, the long-term survival benefit of NAC in LACC remains debated, due to a lack of conclusive clinical trial results identifying the patients who would benefit most from NAC. This study aimed to assess the efficacy of NAC in patients with LACC based on histological subtype. This retrospective study analyzed 3,709 patients with LACC who underwent curative resection at Harbin Medical University Cancer Hospital between 2014 and 2018. Patients were grouped into two groups: neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) groups. Propensity score matching (PSM) was used to adjust for confounders, and survival outcomes of the two groups across different histological subtypes were evaluated using Kaplan-Meier (K-M) curves and log-rank tests. Patients with non-mucinous adenocarcinoma (NMAC) treated with NAC had a significantly improved 5-year OS rate (76.3% vs. 69.2%, p = .039) and DFS rate (67.2% vs. 60.1%, p = .041) compared with patients treated with AC. However, there was no significant difference in OS and DFS between the two treatment groups among patients with mucinous adenocarcinoma (MAC) and signet ring cell carcinoma (SRCC). In patients with LACC, the prognostic value of NAC varied by histology. NMAC may serve as a predictor of improved long-term survival benefit from NAC in these patients.Keywords
This publication has 40 references indexed in Scilit:
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC TrialJournal of Clinical Oncology, 2009
- Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single instituteInternational Journal of Colorectal Disease, 2009
- Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trialsBritish Journal of Cancer, 2007
- Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial TractUrology, 2007
- Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089Journal of Clinical Oncology, 2005
- Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancerAnnals of Oncology, 2005
- Two subtypes of mucinous colorectal carcinoma characterized by laser scanning cytometry and comparative genomic hybridization.International Journal of Oncology, 2004
- Metastatic Tumor Doubling Time: Most Important Prehepatectomy Predictor of Survival and Nonrecurrence of Hepatic Colorectal Cancer MetastasisWorld Journal of Surgery, 2004
- Multimodality Management of Urachal Carcinoma: The M. D. Anderson Cancer Center ExperienceJournal of Urology, 2003
- Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapyThe American Journal of Surgery, 1998